1. Introduction {#s0005}
===============

The diagnosis of Alzheimer\'s disease (AD) can be improved by the use of biomarkers ([@bb0005]; [@bb0020]; [@bb0075]). Structural MRI, which provides biomarkers of neuronal loss, is an integral part of the clinical assessment of patients with suspected AD ([@bb0005]; [@bb0020]; [@bb0075]). Several studies have shown that atrophy estimates in characteristically vulnerable brain regions, particularly the hippocampus and entorhinal cortex, reflect disease stage and are predictive of progression of mild cognitive impairment (MCI) to AD ([@bb0030]). The clinical utility of structural MRI in differentiating AD from other diseases, such as vascular or non-AD dementia, has been also established ([@bb0030]). However, the value of structural MRI will be increased by standardization of acquisition and analysis methods, and by development of robust algorithms for automated assessment. All of these are needed to achieve the ultimate goal of individual patient diagnosis with a single cross-sectional structural MRI scan and for structural MRI to be definitely qualified by regulatory agencies as a biomarker for enrichment of pre-dementia AD trials ([@bb0040]).

Previous work in computer-aided classification of AD and MCI patients has used several machine learning methods applied to structural MRI ([@bb0085]). The most popular among these methods is Support Vector Machine (SVM) ([@bb0085]). SVM extracts high-dimensional, informative features from MRI to build predictive classification models that facilitate the automation of clinical diagnosis ([@bb0085]). However, feature definition and extraction typically rely on manual/semi-automatic outlining of brain structures, which is laborious and prone to inter- and intra-rater variability, or complex image pre-processing, which is time-consuming and computationally demanding.

An alternative family of machine learning methods, known as deep learning algorithms, are achieving optimal results in many domains such as speech recognition tasks, computer vision and natural language understanding ([@bb0070]) and, more recently, medical analysis ([@bb0025]; [@bb0115]; [@bb0125]). Deep learning algorithms differ from conventional machine learning methods by the fact that they require little or no image pre-processing and can automatically infer an optimal representation of the data from the raw images without requiring prior feature selection, resulting in a more objective and less bias-prone process (LeCun et al., 2015; [@bb0115]). Therefore, deep learning algorithms are better suited for detecting subtle and diffuse anatomical abnormalities (LeCun et al., 2015; [@bb0115]). Recently, deep learning has been successfully applied to the Alzheimer\'s Disease Neuroimaging Initiative (ADNI) dataset to identify AD patients from healthy controls ([Table 1](#t0005){ref-type="table"}) (for a review see ([@bb0115])). Only one study so far has applied deep learning algorithms, without *a priori* feature selection (considering gray matter \[GM\] volumes as input), to the prediction of AD development within 18 months in individuals with MCI using ADNI structural MRI scans ([@bb0105]) ([Table 1](#t0005){ref-type="table"}).Table 1Literature review on structural MRI (T1-weighted images) and deep learning in AD and MCI patient classification.Table 1Studies (chronological order)DatasetSample sizeMCI conversion to AD?Deep learning architectureInputData augmentationValidationTransfer learningClassifications & Accuracy (%)Natural Image Bases to Represent Neuroimaging Data ([@bb0045])ADNI200 AD, 232 HC, 411 MCINOSparse Auto-encoder with Convolutional Neural NetworkNormalized 3D T1-weighted imagesYES (serial scans from each subject)Independent sampleNOAD *vs* HC: 95.24% MCI *vs* HC: 92.23% AD *vs* MCI: 84.07%Predicting Alzheimer\'s disease: a neuroimaging study with 3D convolutional neural networks ([@bb0080])ADNI755 AD, 755 HC, 755 MCINOSparse Auto-encoder with 3D Convolutional Neural NetworkNormalized 3D T1-weighted imagesYES (serial scans from each subject)Independent sampleNOAD *vs* HC: 95.4% MCI *vs* HC: 92.1% AD *vs* MCI: 86.8% AD *vs* MCI *vs* HC: 89.5%Alzheimer\'s disease diagnostics by a deeply supervised adaptable 3D convolutional network ([@bb0055])ADNI70 from each class (AD, HC, MCI)NO3D convolutional autoencoderNormalized 3D T1-weighted imagesNONot specifiedYESAD *vs* HC: 99.3% MCI *vs* HC: 94.2% AD *vs* MCI: 100% AD *vs* MCI *vs* HC: 94.8%\
AD+MCI *vs* HC: 95.7%DeepAD: Alzheimer\'s Disease Classification *via* Deep Convolutional Neural Networks using MRI and fMRI ([@bb0095])ADNI91 AD, 211 HCNOConvolutional Neural NetworkNormalized 3D T1-weighted imagesYES (3D to 2D conversion)Not specifiedNOAD *vs* HC: 98.84%Deep ensemble learning of sparse regression models for brain disease diagnosis ([@bb0105])ADNI186 AD, 226 HC, 167 converters MCI, 226 stable MCIYESMultiple sparse regression models with deep Convolutional Neural NetworkGM volumesNO10-fold cross validationNOAD *vs* HC: from 84.69 to 91.02% MCI *vs* HC: from 66.78 to 73.02% Converters MCI *vs* stable MCI: from 66.39 to 74.82%[^2]

The aim of the present study was to build and validate a deep learning algorithm (specifically convolutional neural networks \[CNN\]) that can predict the individual diagnosis of AD and the development of AD in MCI patients based on a single cross-sectional brain structural MRI scan. A robust diagnostic marker should adapt to various datasets to diminish discrepancies in data distribution and biases toward specific groups ([@bb0040]). One of the most important caveats of previous works is the single-center origin of imaging data that limits the generalizability of findings. In light of this, one of the main goal and novelty of our study was to overcome this limit by comparing data from different centers, neuroimaging protocols and scanners, in order to reach both reliability and reproducibility of results.

2. METHODS {#s0010}
==========

2.1. Participants {#s0015}
-----------------

We used the structural brain MRI scans from the ADNI dataset ([ADNI.LONI.USC.EDU](http://adni.loni.usc.edu){#ir0010}). The ADNI was launched in 2003 as a public private partnership, led by Principal Investigator Michael W. Weiner, MD. The primary goal of ADNI has been to test whether serial MRI, positron emission tomography, other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of MCI and early AD. For up-to-date information, see [WWW.ADNI-INFO.ORG](http://www.adni-info.org){#ir0015}. A total of 1409 subjects (294 patients with probable AD, 763 patients with MCI, and 352 healthy controls) were considered in this study ([Table 2](#t0010){ref-type="table"}). Standard 3 T baseline T1-weighted images were included from the ADNI dataset. We included all ADNI1, ADNI2 and ADNI-GO subjects that had baseline 3D T1-weighted scans. After 36 months, 253 MCI patients (33%) converted clinically to AD (c-MCI).Table 2Demographic and clinical features of AD and MCI patients and healthy controls from the ADNI dataset.Table 2HCADc-MCIs-MCIP AD *vs* HCP c-MCI *vs* HCP s-MCI *vs* HCP AD *vs* c-MCIP AD *vs* s-MCIP c-MCI *vs* s-MCIN352294253510Age \[years\]74.53 ± 6.16 (56.20--89.60)75.13 ± 7.75 (55.10--90.90)73.80 ± 7.35 (55.00--88.30)72.33 ± 7.68 (54.40--91.40)1.001.00\<0.0010.20\<0.0010.05Gender \[women/men\]185/167136/158102/151223/2870.120.0030.010.170.510.35Education \[years\]16.30 ± 2.76 (6--20)15.14 ± 3.02 (4--20)15.76 ± 2.84 (6--20)16.02 ± 2.82 (4--20)\<0.0010.130.930.07\<0.0011.00CDR sum of boxes0.03 ± 0.12 (0--1)4.46 ± 1.61 (1−10)1.95 ± 0.97 (0.5--5.5)1.29 ± 0.76 (0.5--4)\<0.001\<0.001\<0.001\<0.001\<0.001\<0.001MMSE29.07 ± 1.16 (24--30)23.12 ± 2.1 (18--27)26.91 ± 1.78 (23−30)27.99 ± 1.71 (23--30)\<0.001\<0.001\<0.001\<0.001\<0.001\<0.001[^3]

An independent dataset of 3D T1-weighted images were obtained from 229 subjects (hereafter named as "Milan" dataset) including 124 patients with probable AD ([@bb0075]), 50 patients with MCI ([@bb0005]), and 55 healthy controls who were recruited consecutively at the Department of Neurology, Scientific Institute and University Vita-Salute San Raffaele, Milan ([Table 3](#t0015){ref-type="table"}). After 36 months, 27 (54%) MCI patients converted clinically to AD. An experienced neurologist blinded to MRI results performed clinical assessments. Healthy controls with no history of neurologic, psychiatric or other major medical illnesses were recruited among friends and spouses of patients and by word of mouth ([Table 3](#t0015){ref-type="table"}).Table 3Demographic, clinical and neuropsychological features of AD and MCI patients and healthy controls from the Milan dataset.Table 3HCADc-MCIs-MCIP AD *vs* HCP c-MCI *vs* HCP s-MCI *vs* HCP AD *vs* c-MCIP AD *vs* s-MCIP c-MCI *vs* s-MCIN551242723Age \[years\]67.1 ± 6.8 (56.1--81.8)68.3 ± 8.1 (48.5--85.6)71.6 ± 7.5 (55.3--85.7)68.2 ± 6.4 (52.1--80.7)1.000.081.000.251.000.71Gender \[women/men\]29/2669/5513/1410/130.420.440.310.310.200.48Education \[years\]12.2 ± 4.7 (5--24)9.5 ± 4.5 (1--18)10.4 ± 4.4 (4--18)11.3 ± 3.7 (5--18)0.0010.561.001.000.381.00Disease duration \[years\]--3.5 ± 2.0 (0.0--10.2)3.0 ± 1.5 (1.0--6.1)3.0 ± 1.7 (0.6--6.0)------0.650.641.00CDR--1.2 ± 0.6 (0.5--3)0.5 ± 0.2 (0.5--1)0.5 ± 0.1 (0.5--1)------\<0.001\<0.0011.00CDR sum of boxes--5.1 ± 2.2 (2−12)2.2 ± 1.0 (1--4.5)2.4 ± 1.1 (1--4.5)------\<0.001\<0.0011.00MMSE29.1 ± 1.0 (26--30)19.8 ± 4.5 (9--27)26.8 ± 1.7 (24--30)27.4 ± 2.0 (23--30)\<0.0010.170.64\<0.001\<0.0011.00  Verbal memoryRAVLT, immediate recall43.4 ± 9.0 (25--60)15.0 ± 7.1 (0--40)19.6 ± 6.0 (8--32)23.7 ± 7.8 (10--34)\<0.001\<0.001\<0.0010.110.0010.62RAVLT, delayed recall8.9 ± 3.3 (4--15)0.4 ± 0.9 (0--3)1.2 ± 1.9 (0--6)1.9 ± 2.1 (0--7)\<0.001\<0.001\<0.0010.530.041.00Digit span, forward5.9 ± 1.1 (4--9)4.6 ± 1.1 (0--7)4.9 ± 0.8 (3--6)5.4 ± 1.2 (3--8)\<0.0010.010.470.990.021.00Memory prose9.7 ± 7.0 (3--17)2.2 ± 2.5 (0--14)5.5 ± 3.1 (0−11)7.3 ± 3.6 (2--15)\<0.0010.141.00\<0.001\<0.0010.30  Visuospatial memorySpatial span, forward5.1 ± 1.0 (4--7)3.0 ± 1.2 (0--6)4.2 ± 0.7 (3--6)4.5 ± 0.5 (4--5)\<0.0010.020.46\<0.001\<0.0011.00Rey\'s figure, recall17.7 ± 5.9 (9--33)2.8 ± 3.8 (0--26)5.5 ± 3.0 (0−13)10.0 ± 5.5 (2−21)\<0.001\<0.001\<0.0010.03\<0.0010.002  Visuospatial abilitiesRey\'s figure, copy33.2 ± 2.4 (27--36)15.3 ± 10.0 (0--35)24.3 ± 9.1 (0--36)27.7 ± 5.3 (15--36.0)\<0.0010.0010.15\<0.001\<0.0010.99Clock Drawing Test8.9 ± 0.9 (8--10)3.5 ± 3.9 (0−10)7.1 ± 3.2 (0--10)8.0 ± 3.1 (0--10)\<0.0011.001.000.002\<0.0011.00  Attention and executive functionsAttentive matrices48.8 ± 7.6 (32--57)31.0 ± 12.7 (2--56)43.3 ± 8.2 (30--56)46.5 ± 7.9 (33--58)\<0.0010.431.00\<0.001\<0.0011.00Raven coloured progressive matrices29.9 ± 3.8 (22--35)16.8 ± 8.2 (2--35)23.3 ± 5.5 (10−31)26.1 ± 5.9 (9--33)\<0.0010.010.37\<0.001\<0.0011.00Semantic fluency42.4 ± 8.9 (27--60)19.0 ± 9.0 (3--55)29.5 ± 7.0 (16--42)32.7 ± 10.3 (12--55)\<0.001\<0.0010.001\<0.001\<0.0011.00Phonemic fluency36.7 ± 10.4 (18--55)16.6 ± 10.3 (0--43)24.0 ± 10.3 (11--48)30.6 ± 13.8 (10--66)\<0.001\<0.0010.320.01\<0.0010.22  LanguageToken test33.2 ± 2.1 (29--36)25.5 ± 5.8 (5--36)30.5 ± 3.1 (24--35)31.6 ± 2.3 (25--34)\<0.0010.261.00\<0.001\<0.0011.00[^4]

In both datasets (ADNI and Milan), the conversion from MCI to dementia was established clinically. This was a judgment made by skilled clinicians on the determination of whether or not there was significant interference in the ability to function at work or in usual daily activities based on the information obtained from the patient and from a knowledgeable caregiver.

This cross-sectional study was approved by the Local Ethical Committee on human studies and written informed consent from all subjects was obtained prior to their enrolment.

2.2. MRI acquisition protocol {#s0020}
-----------------------------

Details about the ADNI MRI data acquisition protocol can be seen in ADNI\'s official webpage ([ADNI.LONI.USC.EDU](http://adni.loni.usc.edu){#ir0020}). Patients and healthy controls from the Milan dataset underwent a 3.0 T MR scan using a Philips Medical Systems Intera machine. The following sequences were acquired: (i) T2-weighted spin echo (SE) (repetition time \[TR\] = 3000 ms, echo time \[TE\] = 85 ms, flip angle = 90°, echo train length = 15, thickness = 3 mm, 46 contiguous axial slices, field of view \[FOV\] = 230 × 208 mm^2^, matrix size = 256 × 242); (ii) fluid-attenuated inversion recovery (FLAIR) (TR = 11,000 ms, TE = 120 ms, inversion time = 2800 ms, flip angle = 90°, echo train length = 21, thickness = 3 mm, 46 contiguous axial slices, FOV = 230 × 183 mm^2^, matrix size =256 × 192); and (iii) 3D T1-weighted fast field echo (TR = 25 ms, TE = 4.6 ms, flip angle = 30°, thickness = 1 mm, 220 contiguous axial slices, and in-plane resolution 0.89 × 0.89 mm^2^, FOV = 230 × 230 mm^2^, matrix size = 256 × 256).

2.3. MRI analysis {#s0025}
-----------------

An experienced observer, blinded to patients\' identity, performed MRI analysis. MRI analysis and CNN procedures were performed on a Dell Powerdge T630 Linux, including high-performance GPU NVIDIA Tesla K40, with 2880 CUDA cores and High Frequency Intel Xeon E5--2623 v3 with 78 GB memory overall.

3D T1-weighted images from both datasets were normalized to the MNI space using Statistical Parametric Mapping (SPM12; [HTTP://WWW.FIL.ION.UCL.AC.UK/SPM](http://www.fil.ion.ucl.ac.uk/spm){#ir0025}[/]{.ul}) and the Diffeomorphic Anatomical Registration Exponentiated Lie Algebra (DARTEL) registration method ([@bb0010]). Briefly, (i) T1-weighted images were segmented to produce GM, white matter (WM) and cerebrospinal fluid (CSF) tissue probability maps in the Montreal Neurological Institute (MNI) space; (ii) the segmentation parameters obtained from the step (i) were imported in DARTEL; (iii) the rigidly aligned version of the images previously segmented (i) was generated; (iv) the DARTEL template was created and the obtained flow fields were applied to the modulated 3D T1-weighted images of single subjects (generated by the segmentation step) to warp them to the common DARTEL space and then modulated using the Jacobian determinants. Since the DARTEL process warps to a common space that is smaller than the MNI space, we performed an additional transformation as follows: (v) the modulated 3D T1-weighted images from DARTEL were normalized to the MNI template using an affine transformation estimated from the DARTEL GM template and the *a priori* GM probability map without resampling ([HTTP://BRAINMAP.WISC.EDU/NORMALIZEDARTELTOMNI](http://brainmap.wisc.edu/normalizeDARTELtoMNI){#ir0030}).

2.4. Convolutional neural networks {#s0030}
----------------------------------

Mimicking how the human brain processes information, the building blocks of deep learning networks, known as 'artificial neurons', are organized in layers in which each 'neuron' is fully connected to all 'neurons' in the next layer through weighted connections ([@bb0070]). Briefly, deep learning networks (i) 'learn' from a series of inputs that are the data inputted into the model, (ii) propagate learned information through the network from the input to the output layer, (iii) calculate the error signal (*i.e.*, difference between the network output and target value), and (iv) propagate the error signal back. After that, deep learning networks adjust their weights and repeat all the steps from (i) to (iv) until the error becomes as small as possible. Finally, trained networks are used to blind-predict the class of new (unseen) observations.

There are several architectures currently used for deep learning ([@bb0115]). CNNs are a special type of feedforward neural networks that were initially designed to process images regardless various distortions, and as such are biologically-inspired by the visual cortex ([@bb0065]). As illustrated in [Fig. 1](#f0005){ref-type="fig"}, standard CNNs typically alternate convolutional and max-pooling layers followed by a small number of fully-connected layers, in addition to the input and output layers. In the convolutional layer, which is the first neuronal layer receiving an input signal, neurons identify the main features that characterize the images, storing the information into a 'feature map' containing the relationship between the neurons and their features. Immediately after each convolutional layer, it is convention to apply a nonlinear layer (or activation layer). This layer, which just changes all the negative activations to 0, increases the nonlinear properties of the model and the overall network without affecting the receptive fields of the convolutional layer. The most common activation function is the Rectified Linear Unit, due to its faster training speed. A pooling (or subsampling) layer follows, which performs a downsampling operation along the spatial dimension. The last layers in the network are the fully-connected layers, where the neurons are connected to all neurons from the previous layer. CNN properties reduce the number of parameters that must be learned, thus improving training performance upon general deep learning algorithms ([@bb0070]).Fig. 1Architecture of a typical convolutional neural network. a) Input layer: the data is given to the network. b) Convolutional layer: neurons identify the main features that characterize the images, storing the information into a 'feature map' (*e.g.*, red, blue and yellow blocks). c) Pooling layer: the size of each feature map is reduced with a downsampling operation along the spatial dimension (*e.g.*, red, blue and yellow blocks). d) Fully-connected layer: the neurons are connected to all neurons from the previous layer. e) Output layer: the step that returns the probability of the input data to belong to each class.Fig. 1

Here, we introduce in detail the CNNs implemented in our study. First, given the volumetric nature of MR images, a network architecture that uses 3D convolutions was developed. The inputs were normalized 3D T1-weighted images and the outputs to be predicted were subject groups. The architecture of the network contains: 12 repeated blocks of convolutional layers (2 blocks with 50 kernels of size 5 × 5 × 5 with alternating strides 1 and 2 and 10 blocks with 100 to 1600 kernels of size 3 × 3 × 3 with alternating strides 1 and 2); a Rectified Linear Unit (activation layer); a fully-connected layer; and one output (logistic regression) layer. The network used in our study differs from the standard CNNs as max-pooling layers were replaced by standard convolutional layers with stride of 2 ('all convolutional network'([@bb0100])). The \"all convolutional network\" is a basic architecture reaching good performance without the need for complicated activation functions, any response normalization or max-pooling ([@bb0100]). All software was written in Python using Theano, a scientific computing library with support for machine learning and GPU computing.

2.5. Experiments {#s0035}
----------------

Performance of the 3D CNN was validated and tested on patients and controls, with six binary classifications: AD *vs* HC, c-MCI *vs* HC, stable MCI (s-MCI) *vs* HC, AD *vs* c-MCI, AD *vs* s-MCI, c-MCI *vs* s-MCI. For each classification, the CNN was evaluated firstly on ADNI dataset and then on ADNI + Milan dataset (12 classifications in total). Each classification included three steps ([Fig. 2](#f0010){ref-type="fig"}): (i) training, (ii) validation, and (iii) testing. First, MRI data of each classification dataset was randomly split into a large training and validation set (90% of images) and a testing set (10% of images). Data augmentation was then applied on images selected for training and validation (not testing) in order to generate additional artificial images and consequently prevent overfitting, which can occur when a fully connected layer occupies most of the parameters. Providing a CNN with more training and validation examples can reduce overfitting. Data augmentation strategy consisted of deformation, flipping, scaling, cropping and rotation of images (see examples in [Fig. 3](#f0015){ref-type="fig"}). We augmented the dataset of each subject group in any of the 12 classifications up to 1000. Each augmented dataset was randomly split into two subsets (90% for training and 10% for validation). For each classification, (i) CNN was trained on the augmented dataset and (ii) validated using a 10-fold cross validation. To improve the performance of our classifier, a so-called transfer learning was applied, *i.e.*, weights of the CNN used to classify ADNI AD *vs* HC were transferred to the other CNNs and used as (pre-trained) initial weights ([@bb0055]). "Transferring" the learned features reduces training time and increases the network efficiency.Fig. 2Flowchart of the main steps of the experiments performed. MRI data of each classification dataset (AD *vs* HC, c-MCI *vs* HC, s-MCI *vs* HC, AD *vs* c-MCI, AD *vs* s-MCI, c-MCI *vs* s-MCI) were randomly split into a large training and validation set (90% of images) and a testing set (10% of images). Data augmentation was applied on images selected for training and validation. See text for further details.Fig. 2Fig. 3Examples of images after data augmentation, *i.e.*, deformation, cropping, rotation, flipping, and scaling. Axial and coronal images are shown. A = anterior; L = left; P = posterior; R = right.Fig. 3

CNN was finally used to classify raw images of the testing set (iii). CNN\'s performance was evaluated by several performance measures, *i.e.* sensitivity, specificity and accuracy. Sensitivity measures the proportion of true positives correctly identified, whereas specificity refers to the proportion of true negatives correctly identified. The accuracy of a classifier represents the overall proportion of correct classifications.

3. RESULTS {#s0040}
==========

[Table 4](#t0020){ref-type="table"} reports binary classification performances of the CNNs in the testing datasets. The results demonstrated that high levels of accuracy were achieved in all the comparisons. Highest accuracy, sensitivity and specificity (higher than 98%) were obtained in the AD *vs* HC classification tests using both the ADNI dataset and the combined ADNI + Milan dataset ([Table 4](#t0020){ref-type="table"}). CNNs were also able to discriminate between c-MCI patients and HC with an optimal performance (accuracy, sensitivity and specificity values higher than 86%; [Table 4](#t0020){ref-type="table"}). In distinguishing c-MCI from s-MCI subjects, CNNs reached an accuracy up to about 75%, with no differences between ADNI and non-ADNI images ([Table 4](#t0020){ref-type="table"}).Table 4Binary classification results on testing datasets.Table 4AccuracySensitivitySpecificityAD *vs* HCADNI dataset99.2%98.9%99.5%ADNI + Milan dataset98.2%98.1%98.3%c-MCI *vs* HCADNI dataset87.1%87.8%86.5%ADNI + Milan dataset87.7%87.3%88.1%s-MCI *vs* HCADNI dataset76.1%75.1%77.1%ADNI + Milan dataset76.4%75.1%77.8%AD *vs* c-MCIADNI dataset75.4%74.5%76.4%ADNI + Milan dataset75.8%74.8%77.1%AD *vs* s-MCIADNI dataset85.9%83.6%88.3%ADNI + Milan dataset86.3%84.0%88.7%c-MCI *vs* s-MCIADNI dataset75.1%74.8%75.3%ADNI + Milan dataset74.9%75.8%74.1%[^5]

4. DISCUSSION {#s0045}
=============

Effective and accurate AD diagnosis is critical for early treatment. Therefore many researchers have devoted their efforts to develop a computer-aided system, which can diagnose AD in the early stages and on an individual basis ([@bb0085]; [@bb0115]). In this study, we built and validated a deep learning algorithm that predicts the individual diagnosis of AD and MCI who will convert to AD based on a single cross-sectional brain structural MRI scan. Results showed that our CNN was highly-performing in differentiating AD and MCI patients from healthy controls and good-performing in predicting conversion to AD within 36 months. Importantly, our algorithm performed well without any prior feature engineering and regardless the variability of imaging protocols and scanners, demonstrating that it is exploitable by not-trained operators and likely to be generalizable to unseen patient data.

The strengths of our approach relative to previous deep learning studies in AD ([@bb0115]) ([Table 1](#t0005){ref-type="table"}) are several. First, heterogeneous MRI data proved to be a challenge for all evaluated models, with performance deteriorating more when images were obtained using different MR protocols and areas of the images known to be important for identity inference are inhomogeneous, deformed or lacking ([@bb0050]; [@bb0110]). Structured programs aimed at standardizing and harmonizing MRI acquisition and analysis for AD diagnosis and management are ongoing in research settings ([@bb0035]; [@bb0090]; [@bb0120]). However, data obtained in these selected frameworks might not be representative of real-world populations. This is one of the main reasons why current diagnostic criteria for AD are extremely cautious on recommending the use of MRI in a clinical setting ([@bb0005]; [@bb0020]; [@bb0075]). In our experiments, CNN was trained, validated and tested using two datasets obtained by different MR protocols and scanners in order to capture the full spectrum of heterogeneity among data and provide a less dataset-specific approach. In fact, our approach overcomes the caveats of previous works, which have obtained data from single-center datasets leading to a limited reproducibility of findings.

We also observed that the studied model is not affected by image quality to different degrees as provided by data augmentation. Second, transfer learning from the AD *vs* controls ADNI comparison was applied for computational efficiency ([@bb0055]). Models trained with AD and control subjects can be particularly effective when attempting to distinguish c-MCI and s-MCI patients, as the differences among MCI groups are expected to be smaller than those between AD and controls ([@bb0015]). Therefore, a pre-trained model is the ideal tool to be used in routine clinical practice because it is a less time-consuming task and can provide high performance in distinguishing only slightly different images. Our approach is finally unique as we used a simplified CNN architecture called "all convolutional network", which is optimized to achieve state-of-the-art performances with the minimum necessary CNN components ([@bb0100]). The great advantage of such a network model relative to standard CNNs is that it greatly reduces the number of network parameters and thus serves as a form of regularization ([@bb0100]).

As in previous supervised and unsupervised machine learning studies ([@bb0085]; [@bb0115]) ([Table 1](#t0005){ref-type="table"}), accuracy in identifying c-MCI from s-MCI patients was not as high as when classifying AD or MCI patients from healthy controls. Using deep neural networks, combined with sparse regression models, a recent structural MRI study obtained a similar accuracy in identifying c-MCI patients ([@bb0105]). Importantly, multiple biomarker modalities may help enhance the diagnostic accuracy in MCI population. The most widely accepted diagnostic criteria for AD assume that the greatest accuracy can be achieved with a combination of amyloidosis and neurodegeneration biomarkers ([@bb0005]; [@bb0020]; [@bb0075]). It is worth noting that the accuracy achieved by our algorithm is also comparable to that of previous studies applying deep learning algorithms on multimodal datasets (*e.g.*, clinical, cognitive, CSF, MRI, and PET ([@bb0115])), thus suggesting that there may be a huge margin of improvement using our simplified deep learning architecture in a multimodal biomarker framework. In light of this, in particular for the crucial comparison between c-MCI and s-MCI, future studies should consider to add other MRI sequences (such as functional MRI and/or diffusion tensor imaging), PET and CSF biomarkers together with neuropsychological scores and genetic information in order to improve the power of classification.

There are some limitations that need to be considered. First, we cannot exclude the presence of future c-MCI among s-MCI patients. Indeed, a longer clinical follow up may improve clinical diagnosis and thus our algorithm performance. Second, as previously mentioned, our model should be tested in combination with clinical, cognitive, genetic, PET and CSF biomarkers to improve the prediction of full-blown dementia development in MCI patients. Third, AD is a clinically heterogeneous disease and this should not be ignored. Effective diagnostic tools should be developed that can deal with atypical AD presentations, like posterior cortical atrophy and logopenic variant of primary progressive aphasia. Finally, neurodegeneration due to AD occurs years, even decades, before the clinical onset ([@bb0060]). Future studies are warranted to test the accuracy of the procedure in identifying subjects in the preclinical phase of the disease and, potentially, as a screening tool in the general population to identifying people at high risk of developing dementia.

In conclusion, CNNs show promises for building a model for the automated, individual and early detection of AD and thus accelerating the adoption of structural MRI in routine practice to help assessment and management of patients.
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